ADC Therapeutics (ADCT) Registration Filing summary

Company overview and business model

• Commercial-stage global pioneer in antibody drug conjugates (ADCs), with a focus on oncology and a lead product, ZYNLONTA, approved for relapsed or refractory DLBCL in multiple major markets.

• Pursuing international expansion and label extension for ZYNLONTA through ongoing Phase 3 and Phase 1b clinical trials and investigator-initiated studies in additional lymphoma indications.

• Headquartered in Switzerland with operations in New Jersey, leveraging specialized capabilities from clinical development to commercialization.

Financial performance and metrics

• May receive up to $37.5 million in proceeds if warrants are exercised in cash, supporting working capital and general corporate purposes.

• Financial statements for the year ended December 31, 2025, are incorporated by reference and audited by PricewaterhouseCoopers SA.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling shareholders; proceeds from warrant exercises (if in cash) will be used for working capital, R&D, and commercialization activities.

• No plans to pay cash dividends in the foreseeable future; intends to retain earnings to fund business development and expansion.